Mind-molding psychedelic drugs could treat depression and other mental illnesses Study examines long-term effects of antidepressants on body weightWidespread antidepressant use may be contributing to weight gain in the population New Canadian guideline for deprescribing benzodiazepines, zopiclone and zolpidem Provides guidance on when and how to safely taper and stop benzodiazepine receptor agonists being used for insomnia Updated guidelines now available for managing bipolar disorder Provide a comprehensive evidence-based review of treatment for the various phases of bipolar disorder Updated Canadian ADHD practice guidelines now available Address the diagnosis and management of attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults. What happened to Asperger's syndrome? Viibryd: new antidepressant launches in Canada Vilazodone acts as a serotonin reuptake inhibitor and a partial agonist at 5-HT1A receptors Foquest: new once-daily stimulant designed for adults with ADHD Controlled-release methylphenidate product has one-hour onset and 16-hour duration of action New Canadian guideline and algorithm for deprescribing antipsychotics Provides advice for safe tapering and stopping antipsychotics used for insomnia or BPSD Palliative care in patients with dementia: how pharmacists can assist First Previous 22 23 24 25 26 Next Last